BBB

PHARMESIS INTL

No trades
See on Supercharts
Market capitalization
‪2.21 M‬SGD
−0.034SGD
‪−939.92 K‬SGD
‪8.65 M‬SGD
Beta (1Y)
0.92

About PHARMESIS INTL

CEO
Xue Dan Wu
Headquarters
Singapore
Founded
1996
ISIN
SG1BH6000003
FIGI
BBG000CP0KW0
Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates through the following segments: Western Drugs, Traditional Chinese Medicine Formulated Drugs, and Distribution. The Western Drugs segment involves in the chemically formulated drugs and is marketed under the Kinna brand. The Traditional Chinese Medicine Formulated Drugs segment offers traditional Chinese medicine and is marketed under the Longlife brand. The Distribution segment includes agency products and internally manufactured products which are marketed through the distribution arm. The company was founded in 1996 and is headquartered in Singapore.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BFK is 0.080 SGD — it has decreased by 38.93% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SGX exchange PHARMESIS INTL stocks are traded under the ticker BFK.
BFK stock is 63.75% volatile and has beta coefficient of 0.92. Check out the list of the most volatile stocks — is PHARMESIS INTL there?
Yes, you can track PHARMESIS INTL financials in yearly and quarterly reports right on TradingView.
BFK stock has fallen by 1.23% compared to the previous week, the month change is a 1.23% fall, over the last year PHARMESIS INTL has showed a 25.23% decrease.
BFK net income for the last quarter is ‪−730.37 K‬ SGD, while the quarter before that showed ‪−200.90 K‬ SGD of net income which accounts for −263.54% change. Track more PHARMESIS INTL financial stats to get the full picture.
Today PHARMESIS INTL has the market capitalization of ‪2.21 M‬, it has decreased by 38.93% over the last week.
No, BFK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BFK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMESIS INTL stock right from TradingView charts — choose your broker and connect to your account.
BFK reached its all-time high on Apr 21, 2020 with the price of 0.625 SGD, and its all-time low was 0.080 SGD and was reached on Oct 30, 2023.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMESIS INTL technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMESIS INTL stock shows the sell signal. See more of PHARMESIS INTL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMESIS INTL EBITDA is ‪−164.87 K‬ SGD, and current EBITDA margin is −2.09%. See more stats in PHARMESIS INTL financial statements.